Bladder Cancer detection by urinary methylation markers GHSR/MAL: a validation study
Open Access
- 16 October 2024
- journal article
- research article
- Published by Springer Nature in World Journal of Urology
- Vol. 42 (1) , 1-8
Abstract
Purpose: Although cystoscopy is a reliable tool for detecting bladder cancer, it poses a high burden on patients and entails high costs. This highlights the need for non-invasive and cost-effective alternatives. This study aimed to validate a previously developed urinary methylation marker panel containing GHSR and MAL. Methods: We enrolled 134 patients who underwent cystoscopy because of hematuria, including 63 individuals with primary bladder cancer and 71 with non-malignant findings. Urine samples were self-collected at home and sent via regular mail. Subsequently, DNA was extracted and the hypermethylation of GHSR and MAL was evaluated using quantitative methylation-specific polymerase chain reaction. The performance of methylation markers was assessed using area-under-the-curve (AUC) analysis and sensitivity and specificity based on pre-established cut-off values. Results: Validation of the marker panel GHSR/MAL resulted in an AUC of 0.87 at 79% sensitivity and 80% specificity. Sensitivity was comparable to the previous investigation (P > 0.9), though specificity was significantly lower (P = 0.026). Sensitivity was higher for high-grade tumors compared to low-grade tumors (94% vs. 60%, P = 0.002). Conclusion: Validation of the GHSR/MAL methylation marker panel on at home collected urine samples confirms its robust performance for bladder cancer detection in a hematuria population, and underscores the diagnostic potential for future clinical application.Keywords
This publication has 30 references indexed in Scilit:
- Diagnostic Accuracy of Novel Urinary Biomarker Tests in Non–muscle-invasive Bladder Cancer: A Systematic Review and Network Meta-analysisEuropean Urology Oncology, 2021
- Validation of an mRNA-based Urine Test for the Detection of Bladder Cancer in Patients with HaematuriaEuropean Urology Oncology, 2021
- Predictive value of MCM5 (ADXBLADDER) analysis in urine of men evaluated for the initial diagnosis of bladder cancer: A comparative prospective studyDiagnostic Cytopathology, 2020
- A Novel, non-invasive Test Enabling Bladder Cancer Detection in Urine Sediment of Patients Presenting with Haematuria—A Prospective Multicentre Performance Evaluation of ADXBLADDEREuropean Urology Oncology, 2020
- The global burden of urinary bladder cancer: an updateWorld Journal of Urology, 2019
- Diagnostic predictive value of the Bladder EpiCheck test in the follow‐up of patients with non–muscle‐invasive bladder cancerCancer Cytopathology, 2019
- Patients choose certainty over burden in bladder cancer surveillanceWorld Journal of Urology, 2019
- Epigenetic Alterations in Bladder CancerCurrent Urology Reports, 2018
- Performance of the Bladder EpiCheck™ Methylation Test for Patients Under Surveillance for Non–muscle-invasive Bladder Cancer: Results of a Multicenter, Prospective, Blinded Clinical TrialEuropean Urology Oncology, 2018
- Identification and Validation of the Methylated TWIST1 and NID2 Genes through Real-Time Methylation-Specific Polymerase Chain Reaction Assays for the Noninvasive Detection of Primary Bladder Cancer in Urine SamplesEuropean Urology, 2010